Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

Immunological Reviews

Volumn 239, Issue 1, 2011, Pages 99-108

  Houghton, Michael ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

HCV immunology; HCV prophylactic vaccine; HCV therapeutic vaccine; Hepatitis C virus; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; RIBAVIRIN;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHIMPANZEE; HEPATITIS C; HEPATITIS C VIRUS; MONOTHERAPY; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; VACCINATION;

ADENOVIRIDAE; ANIMALS; DEFECTIVE VIRUSES; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HUMANS; PAN TROGLODYTES; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 78650536657     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00977.x     Document Type: Article

References (73)

1. Gottwein JM, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009;49:364-377.
2. Weiner AJ, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468-3472.
3. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067-5077.
4. Fafi-Kremer S, et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010;207:2019-2031.
5. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009;136:2377-2386.
6. Fuller MJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010;51:378-387.
7. Horner SM, Gale M Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009;29:489-498.
8. Crotta S, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002;195:35-41.
9. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-49.
10. Helle F, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007;81:8101-8111.
11. Stamataki Z, et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007;25:7773-7784.
12. Bartosch B, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217-8229.
13. Timpe JM, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24.
14. Zhang P, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 2009;106:7537-7541.
15. Rosa D, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102:18544-18549.
16. Serra A, et al. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function. J Immunol 2008;181:174-185.
17. Kriegs M, et al. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 2009; 284:28343-28351.
18. Masciopinto F, et al. Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol 2004;34:2834-2842.
19. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005;43:550-552.
20. Lucas M, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE 2007;2:e649.
21. Weiner AJ, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001;75:7142-7148.
22. Lanford RE, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004;78:1575-1581.
23. Osburn WO, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010;138:315-324.
24. Bukh J, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008;82:8183-8195.
25. Prince AM, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 2005;192:1701-1709.
26. Mehta SH, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-1483.
27. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-2441.
28. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-1991.
29. Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. J Hepatol 1999;31(Suppl.):96-100.
30. Spaete RR, et al. Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 1992; 188:819-830.
31. Ralston R, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993;67:6753-6761.
32. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010;84:10159-10168.
33. Chien DY, et al. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 1993;342:933.
34. Choo QL, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-1298.
35. Houghton M, et al. Development of a HCV Vaccine. In: Rizzetto M, Purcell RH, Gerin JL, Verme G eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica, 1997:656-659.
36. Coates S, et al. Protection of chimpanzees against heterologous 1a viral challenge using a gpE1/gpE2 heterodimer vaccine. In: Jilbert AR, Grgacic EVL, Vickery K, Burrell CJ, Cossart YE eds. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease. Sydney: Australian Center for Hepatitis Virology, 2005:118-123.
37. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-966.
38. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003;7:45-66.
39. Bukh J, Forns X, Emerson SU, Purcell RH. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 2001;44:132-142.
40. Ali L, et al. Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol 2010;91:1931-1938.
41. Carneiro VL, et al. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 2010;30:567-573.
42. Thomas DL, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
43. Law M, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-27.
44. Lavillette D, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005;79:6023-6034.
45. Pestka JM, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-6030.
46. Logvinoff C, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004;101:10149-10154.
47. Frey SE, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28:6367-6373.
48. Ray R, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010;202:862-866.
49. Leroux-Roels G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005;1:61-65.
50. Keck ZY, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 2004;78:7257-7263.
51. Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung M, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999;1(Suppl.):36-40.
52. Grakoui A, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
53. Shoukry NH, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
54. Cooper S, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
55. Rollier CS, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45:602-613.
56. Folgori A, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-197.
57. Youn JW, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 2008;82:10896-10905.
58. Wei CJ, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010;329:1060-1064.
59. Lin Y, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82:7492-7503.
60. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007;27:152-160.
61. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
62. Inchauspe G, Bach G, Martin P, Bonnefoy JY. Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol 2009;28:7-19.
63. Transgene.
64. Okairos.
65. Polakos NK, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001;166:3589-3598.
66. Drane D, et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009;5:151-157.
67. Ahlén G, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007;179:4741-4753.
68. Sallberg M. Abstract at Hepdart 2009 meeting on Viral Hepatitis.
69. Intercell.
70. Wedemeyer H, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002;169:3447-3458.
71. Jin HT, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107:14733-14738.
72. Boettler T, et al. T cells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005;79:7860-7867.
73. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-952.